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In the developing spinal cord, oligodendrocyte progenitors (OLPs) originate from the ventral neuroepithelium and the specification of this
lineage depends on the inductive activity of Sonic hedgehog (Shh) produced by ventral midline cells. On the other hand, it has been shown
that OLP identity is acquired by the coexpression of the transcription factors olig2 and nkx2.2. Although initially expressed in adjacent
nonoverlapping domains of the ventral neuroepithelium, these transcription factors become coexpressed in the pMN domain at the time of
OLP specification through dorsal extension of the Nkx2.2 domain. Here we show that Shh is sufficient to promote the coexpression of Olig2
and Nkx2.2 in neuroepithelial cells. In addition, Shh activity is necessary for this coexpression since blocking Shh signalling totally abolishes
Olig2 expression and impedes dorsal extension of Nkx2.2. Although Shh at these stages affects neuroepithelial cell proliferation, the dorsal
extension of the Nkx2.2 domain is not due to progenitor proliferation but to repatterning of the ventral neuroepithelium. Finally, Shh not only
stimulates OLP specification but also simultaneously restricts the ventral extension of the astrocyte progenitor (AP) domain and reduces
astrocyte development. We propose that specification of distinct glial lineages is the result of a choice that depends on Shh signalling.
D 2004 Elsevier Inc. All rights reserved.Keywords: Oligodendrocyte; Astrocyte; Sonic hedgehog; Spinal cord; Chick embryo; Olig2; Nkx2.2Introduction
Although oligodendrocytes (OLs), the myelinating cells
of the CNS, are widely distributed throughout the adult white
and grey matter, oligodendrocyte progenitors (OLPs) arise
from restricted domains of the undifferentiated neuroepithe-
lium. In the spinal cord, in particular, explant culture experi-
ments or the use of early lineage markers have shown that
OLPs are restricted to a small ventral neuroepithelial region,
close to the floor plate (Ono et al., 1995; Pringle and
Richardson, 1993; Pringle et al., 1996; Spassky et al.,
1998; Timsit et al., 1995; Trousse et al., 1995; Yu et al.,0012-1606/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.ydbio.2004.02.015
Abbreviations: AP(s), astrocyte progenitor(s); BMP(s), bone morpho-
genetic protein(s); CNS, central nervous system; OL(s), oligodendrocyte(s);
OLP(s), oligodendrocyte progenitor(s); Shh, Sonic hedgehog.
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E-mail address: agius@cict.fr (E. Agius).1994). OLPs migrate out from these regions to populate the
entire spinal cord, where they actively proliferate and differ-
entiate. The ventral origin of OLPs results, at least in part,
from the signalling events that also induce ventral neuronal
populations. The morphogen protein Sonic hedgehog (Shh),
produced by the notochord and the floor plate, induces
various populations of ventral neurons (Briscoe and Ericson,
1999; Briscoe et al., 2000) and also induces OL development
from undifferentiated neural progenitors (Poncet et al., 1996;
Pringle et al., 1996; Trousse et al., 1995). Shh activity is
required for oligodendrogenesis since absence of Shh sig-
nalling prevents OL development in the spinal cord (Orentas
et al., 1999; Soula et al., 2001) and in the telencephalon
(Nery et al., 2001; Spassky et al., 2001; Tekki-Kessaris et al.,
2001). Recent work suggests the alternative FGF-signalling
pathway for promoting OL fate from cultivated neural stem
cells (Chandran et al., 2003; Hsieh et al., 2004). However, it
is unclear whether this pathway also operates in neural
progenitors in vivo.
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ventral subclasses of neurons is now well characterized. The
ventro-dorsal gradient of Shh activity induces the expression
by neural progenitors of a set of homeodomain and bHLH
transcription factors (Briscoe et al., 2000). These factors have
been classified into two categories: class I proteins, which are
repressed by Shh, and class II proteins, which depend on Shh
signalling for their expression. The combinatorial expression
of these factors at each dorso-ventral level of the neuro-
epithelium allows the identity of various classes of neurons in
the ventral neural tube to be defined (Briscoe et al., 2000).
Some of the transcription factors are used within the neuro-
epithelium both during the neurogenic and the gliogenic
phases. In the chick spinal cord, OLPs are found within the
ventral-most Nkx2.2-expressing domain of the neuroepithe-
lium, and not in the Pax6-expressing domain, located just
dorsally (Soula et al., 2001). In addition, a fraction of OLPs
and, subsequently, most OLs, express Olig2, a bHLH tran-
scription factor that is also expressed at earlier stages in motor
neuron progenitors (Lu et al., 2000; Takebayashi et al., 2000;
Zhou et al., 2000, 2001). Loss of function of nkx2.2 drasti-
cally reduces and delays OL development (Qi et al., 2001),
and loss of function of olig2 totally abolishes it (Lu et al.,
2002; Takebayashi et al., 2002; Zhou and Anderson, 2002).
Thus, olig2 appears to play a key role in OL specification.
However, misexpression experiments have shown that both
genes are required to promote OL specification in the chicken
neural tube (Zhou et al., 2001). At the time when OLPs arise,
expression of both Olig2 and Nkx2.2 undergoes dynamic
changes in the neuroepithelium. These transcription factors
are first expressed in mutually exclusive domains but then the
expression domain of Nkx2.2 extends in a dorsal direction,
resulting in partial overlap of both regions (Fu et al., 2002;
Zhou et al., 2001). However, the mechanisms that initiate and
control these changes in expression, in particular the exten-
sion of the Nkx2.2 domain and the coexpression of the two
transcription factors, remain unknown.
Unlike that of OLs, the origin of astrocytes has not yet
been elucidated. Studies of the expression of markers of the
radial glia–astrocyte lineage in the mouse and chicken
suggest that these cells originate from a restricted part of
the neuroepithelium (Pringle et al., 2003; Shibata et al.,
1997) located dorsally to OLPs (Pringle et al., 2003). In
vitro studies have suggested the existence of glial-restricted
progenitors (GRP) derived from multipotent neuroepithelial
stem cells that give rise both to the astrocyte and the OL
lineage (Rao and Mayer-Proschel, 1997). Although no
common molecular mechanism underlying the emergence
of the two lineages has yet been discovered, studies of the
olig1/olig2 double-knockout mouse suggest a possible link
between OL and astrocyte development in vivo, since cells
that normally should have expressed olig genes differentiate
into astrocytes (Zhou and Anderson, 2002). Furthermore, in
vitro studies have shown that Olig2 is able to negatively
control astrocyte differentiation from neural precursors
(Fukuda et al., 2004; Gabay et al., 2003).In the present study, we have analysed the possible
function of Shh produced by the floor plate in generating
the appropriate pattern of expression of transcription factors
required for OL specification. We show that Shh activity is
sufficient for Olig2/Nkx2.2 coexpression and is required for
the maintenance of Olig2 expression and for the dorsal
extension of the Nkx2.2 expression domain. Furthermore,
modification of the size of the Nkx2.2 domain involves
repatterning of the neuroepithelium and not cell prolifera-
tion. Interestingly, Shh signalling regulates neuroepithelial
expression of Fgfr3 and glast, early markers of the astrocyte
lineage, by limiting their ventral extension and simulta-
neously decreases astrocyte differentiation. Altogether, our
results suggest that Shh controls the specification of both
glial lineages by inducing the OL lineage and inhibiting the
astrocyte lineage. We propose that neural progenitors give
rise either to astrocytes or OLs depending on their dorso-
ventral position.Materials and methods
Materials
Fertilized chick eggs (White Leghorn, commercial
source) were incubated at 38jC in a humidified incubator
and embryos were staged according to Hamburger and
Hamilton (1992).
Explants cultures
In all culture experiments, explants were grown in
DMEM (Gibco BRL) supplemented with 10% FCS (Sig-
ma). Ventral neuroepithelial explants (Soula et al., 2001)
were grown on collagen gel-coated 12-mm plastic cover-
slips placed in 14-mm four-well dishes (Nunc). The
recombinant N-terminal fragment of the human Shh pro-
tein (Biogen) was used at concentrations of 12 nM for
neuroepithelial cultures. For flat-mounted spinal cords, a
saturating concentration of 100 nM was used in all experi-
ments. This later concentration very reproducibly inhibited
astrocyte development in our assay. Cyclopamine, a gen-
erous gift of Dr. Frederic Rosa, was used at a concentra-
tion of 4 AM.
For embryonic chick spinal cord cultures, we used a flat
whole-mount preparation already described (Mekki-Dauriac
et al., 2002). Briefly, the cervico-brachial spinal cord from
E4 chick embryos was dissected free of surrounding tissue,
opened along the dorsal midline, and flattened on a nitro-
cellulose membrane (Sartorius) with the neuroepithelial
layer up. The explants were then grown as organotypic
cultures, at the air–medium interface, with or without Shh
protein or cyclopamine for the indicated period of time. For
cell-cycle-blocking experiments, E5 spinal cord flat mounts
were incubated with 5 AM aphidicolin (Sigma) and fixed
after 24 h.
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Control embryos or flat-mounted explants were fixed in
4% paraformaldehyde (PFA) for 4 h at 4jC and processed
for immunohistochemistry or overnight at 4jC and pro-
cessed for in situ hybridisation. The tissues were then
sectioned at 60–80 Am on a vibratome (Leica) before being
processed. Ventral neuroepithelial explants were fixed in 4%
PFA in PBS for 30 min and stained with the appropriate
antibodies.
O4 immunohistochemistry was performed as previously
described (Giess et al., 1992). For the detection of intracel-
lular antigens Nkx2.2, Olig2, Pax6, GFAP, fixed cultures
were permeabilised using Triton-X 100 (0.5% in PBS) and
primary antibody was applied at the appropriate dilution in
0.1% Triton-X 100/PBS and incubated overnight at 4jC.
After incubation, the sections were rinsed in PBS and
further incubated for 30 min with biotinylated secondary
antibody directed against either mouse or rabbit Ig (Amer-
sham, diluted 1:50). After rinsing, biotinylated antibodies
were revealed by 30-min incubation with fluorescein
(FITC)- or rhodamine (TRITC)-coupled streptavidin (Amer-
sham, diluted 1:50). To detect simultaneously Olig2 and
Nkx2.2, immunohistochemistry was performed sequentially,
using first anti-Olig2 antiserum then biotinylated secondary
antibody and fluorescein isothiocyanate (FITC)-coupled
streptavidin as described above; this was followed by anti-
Nkx2.2 antibody, revealed with goat antimouse Alexa-546
antibody (Molecular Probes).
For BrdU staining, organotypic cultures were incubated
for 45 min with BrdU (BrdU labeling and detection kit,
Roche) at the end of the culture period. Explants were then
fixed for 4 h and processed for BrdU staining according to
the manufacturer’s instructions. TUNEL assay (Roche) was
performed as recommended by the manufacturer. In some
experiments, cell nuclei were stained with chromomycin
A3. Sections were rinsed in PBS/MgCl2 (150 mM), incu-
bated 1 h with 100 nM chromomycin A3, rinsed and
mounted with moewiol.
Antibodies
Cells of the OL lineage were identified using O4 anti-
body. The mouse monoclonal O4 antibody recognises
sulfatides at the surface of immature and differentiated
OLs (Bansal et al., 1989; Ono et al., 1995; Sommer and
Schachner, 1981), and the so-called ‘‘prooligodendroblast
antigen’’, expressed before sulfatides by OL progenitors and
early differentiating OLs. Culture supernatant obtained from
O4 hybridoma cells, a gift from Dr R. Bansal, was used
undiluted. The anti-Olig2 antiserum (Takebayashi et al.,
2000) was used at 1:2000 dilution. Astrocytes were
evidenced by an antiserum directed against Glial Fibrillary
Acidic Protein (GFAP; DAKO A/S, Denmark) used at
1:500. All the following monoclonal antibodies (culture
supernatants) were obtained from the Developmental Stud-
E. Agius et al. / Developmen310ies Hybridoma Bank. Motor neurons were identified by
their expression of MNR2 (81.5C10, used at 1:8; Tanabe et
al., 1998). Ventricular cell subpopulations were visualized
either with the anti-Nkx-2.2 antibody used at 1:2 dilution
(74.5A5, Ericson et al., 1996), or the anti-Pax-6 antibody
used at 1:2 dilution (Ericson et al., 1997).
Sections and neuroepithelial explants were analysed with
either a Zeiss LSM-410 or a Leica SP2 confocal micro-
scope, equipped with argon and helium–neon lasers and
appropriate filter combinations for fluorescein and rhoda-
mine, respectively. In all cultures, labelled cells were
counted and results are expressed as the mean F SEM
number of labelled cells per culture or per explant. Signif-
icance of the results was analysed using the Student’s t test.
In situ hybridisation
Olig2, patched, nkx2.2, irx3, sim1, Fgfr3, GFAP, PLP/
D20M and glast transcripts were analysed using the anti-
sense digoxigenin RNA probe. Patched cDNA was a gift
from C. Tabin, Nkx2.2 cDNAwas a gift from J. Rubenstein,
irx3 cDNAwas a gift from T. Ogura, sim1 cDNAwas a gift
from J. Michaud, Fgfr3 was a gift from O. Delapeyriere.
PLP/DM20 cDNAwas a gift from B. Zalc. GFAP cDNAwas
purchased as an EST (pgp1n.pk013.g7) from Delaware
Biotechnology Institute. A glast 595p-cDNA fragment was
generated by PCR using the following primers: upstream
5VTGCTCCACTTGGAATCCTCT3V, downstream 5VCT-
TCAGCTCATGCCGTGATA3V. These primers were defined
using the glast cDNA sequence (accession number,
AF154672). The whole-mount in situ procedure was per-
formed according to Wilkinson (1992).Results
Shh induces coexpression of Olig2 and Nkx2.2 in
neuroepithelial cells
We first investigated whether Shh was sufficient to drive
the coexpression of Olig2 and Nkx2.2 observed in neuro-
epithelial cells in vivo at the time of oligodendrocyte
specification, i.e., E5 to E6 in the chick cervico-brachial
spinal cord (Soula et al., 2001). Since this coexpression
occurs in vivo around E5.5 (Fu et al., 2002; Zhou et al.,
2001), we documented the direct effect of Shh on ventral
neuroepithelial explants isolated in culture at E5, free of
surrounding tissues. Under these conditions, such explants
never generate OL cells, even in long-term cultures, whereas
12 nM Shh rapidly induces numerous OLPs (Soula et al.,
2001). After 48 h of culture, we monitored the expression of
both transcription factors in control and treated explants. In
control conditions, explants displayed very few Olig2-
Nkx2.2 double-labelled cells (12 cells/explant, n = 18; Figs.
1A,C). Shh treatment caused a ninefold increase in the
number of cells coexpressing both factors (105 cells/ex-
Fig. 1. Shh induces the coexpression of Olig2 and Nkx2.2. Neuroepithelial explants were dissected at E5, before OL specification, and cultivated for 2 days
under control conditions (A, D) or with 12 nM Shh protein (B, E). After culture, explants were double-immunostained either with anti-Olig2 and anti-Nkx2.2
antibodies (A, B) or with anti-Olig2 and O4 antibodies (D, E). Control neuroepithelial explants contain very few cells expressing Nkx2.2, Olig2 or both (A, C)
and very few O4+ cells (D, F). After Shh treatment, expression of both Olig2 and Nkx2.2 is induced dramatically. All Olig2+ cells also express Nkx2.2 (B, C).
Concomitantly, Shh induces numerous O4+ cells, all of which also express Olig2 (E, F). C: Quantification of the number of cells per explant expressing
Nkx2.2, Olig2 or both under the different conditions. F: Quantification of the number O4+ cells per explant. Asterisk: Significant difference between control
and treated cultures ( P < 0.01).
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the number of cells expressing Nkx2.2 alone (a fivefold
increase, from 15 to 82 cells per explant). In all cases, most
cells expressing Olig2 also expressed Nkx2.2. To ascertain
that, under our experimental conditions, cells coexpressing
Olig2 and Nkx2.2 corresponded to OLPs, sister cultures
were double-stained with Olig2 and the OLP marker O4. As
previously described, we did not detect significant numbers
of O4 cells in control conditions (Figs. 1D,F), whereas Shh
induced numerous O4+ cells (93 cells per explant; n = 7;
Figs. 1E,F), all of which coexpressed Olig2. These results
suggest that Shh is sufficient to cause the coexpression of
Olig2 and Nkx2.2 in ventral neuroepithelial cells, in con-
junction with OLP specification.
Shh is required for the maintenance of Olig2 expression and
for the extension of the Nkx2.2 expression domain in the
neuroepithelium
To further investigate the relationships between Shh,
transcription factor expression and OLP specification, wedeveloped an organotypic culture system for the spinal
cord, in which the multilayered structure of the tissue is
maintained over several days, enabling progenitor cells to
be distinguished from differentiated cells of the mantle
layer. The spinal cord was isolated at E4, i.e., before OLP
specification, opened dorsally, flat-mounted and main-
tained in culture for 2 days or more (Fig. 2G). To verify
that spinal cords were cultivated under conditions appro-
priate for OL induction, we first analysed O4 expression.
As shown in Fig. 2H, O4 antibody decorated ventral
neuroepithelial cells in bilateral groups of cells, adjacent
to the floor plate, a pattern of expression similar to that
described in E6 embryonic spinal cord in vivo (Ono et al.,
1995; Soula et al., 2001), indicating that OLP specification
had occurred normally.
We then compared the patterns of expression of Olig2,
Nkx2.2 and Pax6 between in vivo spinal cords and these ex
vivo preparations, by counting the number of neuroepithe-
lial cell profiles along the D/V axis. During the period of
neuronal genesis, i.e., until E5, the Nkx2.2 domain was
adjacent to, but did not overlap with the dorsally located
Fig. 2. Shh is required for the coexpression of Olig2 and Nkx2.2 concomitantly with OLP specification. (A–B) Double immunostaining of transverse spinal
cord sections with anti-Olig2 (green) and anti-Nkx2.2 or anti-Pax6 antibodies (red). A: At E5, the Olig2-expressing domain is strictly contiguous to that of
Nkx2.2. The dorso-ventral extension of each of these domains corresponds to about five cell profiles (E). B: At E6, the Nkx2.2 domain has extended dorsally to
about 12 cell profiles (E) and the Olig2 domain is shifted dorsally. In addition, the two domains now overlap leading to coexpression of Nkx2.2 and Olig2 in
some cells. C–D: Between E5 and E6, the Pax6 domain regresses dorsally. The left panel of each image shows Pax6 immunostaining alone, while the right
panel shows Olig2/Pax6 overlay. C: At E5, Pax6 expression is constant down to the dorsal limit of the Olig2 domain and from then on diminishes as a dorso-
ventral gradient. D: At E6, the Pax6 gradient has disappeared, resulting in a dorsal shift of the ventral border of Pax6 expression. Thus, only the dorsal half of
the Olig2 domain coexpresses Pax6. The parallel brackets delineate the position of the Pax6low/Olig2 domain observed at E5. G: Scheme of the organotypic
culture assay. The spinal cord is dissected from the embryo at E4, cultivated for 2 days in vitro (2DIV) or 7 days in vitro (7DIV). At E4 + 2DIV, OLPs are
generated in the ventral neuroepithelium (arrow) and at E4 + 7DIV, OLs have migrated in the ventral white matter, which is displaced laterally under these
culture conditions (arrowheads), and express PLP-DM20. H–Q: Flat-mounted E4 spinal cords were cultivated for 2 days (equivalent to E6) under control
conditions (H, J, L, N, P) or with 4 AM cyclopamine (I, K, M, O, Q). After culture, explants were sectioned and immunostained using antibodies directed
against O4 (H, I), Nkx2.2 (N, O) and Pax6 (P, Q), or prepared for in situ hybridisation with probes for patched (J, K) or olig2 (L, M). H: Under control
conditions, the OL lineage marker O4 is expressed by neuroepithelial cells located on each side of the floor plate and by differentiating OLs that have migrated
in the mantle and marginal layers. I: Cyclopamine treatment abolishes the OL lineage as shown by absence of O4 staining. H–Q: Under control conditions, the
domains of expression of patched (J), olig2 (L), Nkx2.2 (N), Pax6 (P) are comparable in size and position to those observed in vivo. After cyclopamine
treatment, patched (K) and olig2 (M) expression domains are completely abolished, the expression domain of Nkx2.2 (O) is reduced compared to that of
control (N), the domain of Pax6 (Q) is extended ventrally. These images are representative of five to seven different experiments. E: Quantification of the in
vivo domain size at the various stages examined, expressed as the number of cell profiles in each dorso-ventral domain. F: Quantification of domain size for the
various transcription factors, expressed as the number of cell profiles after culture in control or cyclopamine-containing medium. Asterisk: Significant
difference between control and treated cultures ( P < 0.05). Dashed lines highlight the limits of the floor plate (FP). Scale bar represents 50 Am.
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observations (Fu et al., 2002; Zhou et al., 2001). The extent
of the Nkx2.2 and Olig2 domains was 4.8 F 0.2 and 4.6 F
0.3 cells, respectively, and did not vary between E4 and E5
(Fig. 2E). The Pax6 domain was characterised by a markeddorso-ventrally decreasing gradient of expression (Fig. 2C).
We observed that these expression patterns were profoundly
modified after E5, confirming previous results (Fu et al.,
2002; Zhou et al., 2001). In fact, the Nkx2.2 domain
extended dramatically in a dorsal direction (Fig. 2B),
Fig. 3. Proliferation in the neuroepithelium is partly controlled by Shh signalling but this does not account for the repatterning of Nkx2.2, olig2 and Pax6
domains. A–F: Flat-mounted E4 spinal cords were cultivated for 2 days under control conditions (A, C, E), or with 4 AM cyclopamine (B, D, F). A–B: After
culture, explants were prepared for TUNEL assay. No modification of apoptosis can be observed between the control (A) and the cyclopamine-treated culture
(B). C–F: Explants were incubated for 45 min in the presence of BrdU at the end of the culture period and processed for BrdU or Nkx2.2
immunohistochemistry. BrdU incorporation can be observed homogeneously distributed in the neuroepithelium of control spinal cord explants (C). After
cyclopamine treatment, BrdU incorporation is reduced in the ventral neuroepithelium (D) and the size of the Nkx2.2 domain is reduced (F) compared to the
control (E). G: Number of cells incorporating BrdU in the Nkx2.2 domain in control or cyclopamine-treated cultures (n = 3, Asterisk: P < 0.01). H–R: Flat-
mounted E5 spinal cords were cultivated for 24 h under control conditions (H, J, M, O, Q), or with 5 AM aphidicolin (I, K, N, P, R). After culture, they were
stained with anti BrdU antibody (H, I), anti-Nkx2.2 antibody (J, K), anti-Pax6 antibody (M, N), O4 antibody (Q, R) or processed for in situ hybridisation with
the olig2 probe and counterstained with chromomycin A3 (O, P). After aphidicolin treatment, BrdU incorporation is completely abolished (compare H to I).
However, the size of the Nkx2.2 domain observed in aphidicolin-treated explants (K) is not modified compared to control explants (J). L: Quantification of the
Nkx2.2 domain size, expressed as the number of cell profiles (n = 4). The expression profile of Pax6, olig2 and O4 under control conditions (M, O, Q) is not
altered after aphidicolin treatment (N, P, R). FP: floor plate, Scale bar represents 50 Am.
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Fig. 2E). The size of the Olig2 domain, however, did not
change significantly between E5 and E6 (about five cells),
but its ventral border was shifted dorsally by about three cell
diameters (Figs. 2B,E). Thus, the two domains were found
to overlap partially (2.3 F 0.6 cells coexpressing both genes
at this stage). Concomitantly, the ventral border of the Pax6
domain was also displaced dorsally by about five cell
diameters (Figs. 2D,E), through a marked reduction of the
Pax6 protein gradient (Fig. 2D). Interestingly, these mod-
ifications did not continue beyond that stage since, at E7, the
size and the localisation of the domains remained stable
(Fig. 2E). In organotypic conditions, the kinetics of expres-
sion of the three transcription factors were identical to those
observed in vivo. In E4 spinal cords cultivated for 2 days
(equivalent to E6), the Nkx2.2 domain also extended
dorsally over about 12 neuroepithelial cell profiles (Figs.
2N,F) and the Olig2 domain (Fig. 2L) overlapped both
Nkx2.2 (Fig. 2N) and Pax6 (Fig. 2P) domains.
The inductive activity of Shh in neuroepithelial explants
raised the question whether this morphogen is required for
driving the coexpression of Olig2 and Nkx2.2. We analysed
transcription factor expression after treatment with cyclop-
amine, an alkaloid that inhibits Shh signalling (Incardona et
al., 1998) by preventing Smoothened–Gli interactions
(Chen et al., 2002). Cyclopamine treatment (4 AM) effi-
ciently blocked Shh signalling as seen by a total extinction
of the expression of Shh receptor patched (compare Fig. 2K
with Fig. 2J). This treatment completely prevented the
emergence of O4+ OLPs (Fig. 2I), confirming the require-
ment for Shh activity in OLP specification in this system.
Strikingly, expression of olig2 was totally abolished in
spinal cord explants cultivated in the presence of cyclop-
amine (Fig. 2M). Additionally, we observed a drastic
reduction in the size of the Nkx2.2 domain compared to
control explants (Figs. 2O,N). This reduction was paralleledFig. 4. Cyclopamine treatment at E4 does not modify the expression of ventral neu
neuronal subpopulation markers. B–G: Flat-mounted E4 spinal cords were cultiva
(E, F, G). Cyclopamine treatment induces no obvious modification of the expres
MNR2, marker of motoneurons (F) and sim1, marker of V3 interneurons (G), coby a ventral shift of the ventral border of the Pax6 domain
(Figs. 2Q,P). These results indicate that continuous Shh
activity is required for maintaining Olig2 expression in the
pMN domain and for promoting the dorsal extension of the
Nkx2.2+ domain and the regression of the Pax6+ domain
that occur between E5 and E6.
Shh repatterns the ventral neuroepithelium between E5 and
E6
Since Shh is required for the survival of neuroepithelial
cells during early development in vertebrates (Thibert et al.,
2003), the lack of OLP generation in the absence of Shh
signalling could result from apoptosis in the ventral ventric-
ular zone. To test this possibility, cyclopamine-treated and
control spinal cords were stained using the TUNEL assay. In
both types of explants, few TUNEL-positive cells were
observed in the neuroepithelium and we did not observe
any significant difference in apoptosis between control (Fig.
3A) and cyclopamine-treated explants (Fig. 3B). This indi-
cates that the absence of OLPs was not due to cell death.
Two mechanisms could account for the rapid dorsal
expansion of the Nkx2.2 domain mediated by Shh between
E5 and E6: increased cell proliferation or repatterning of the
ventral neuroepithelium. Since Shh is involved in the control
of neuroepithelial cell proliferation in various CNS regions
(Rowitch et al., 1999), we first tested the influence of Shh
signalling on cell proliferation at this stage through analysis
of BrdU incorporation in spinal cord explants cultivated
under control conditions or after addition of cyclopamine.
In control explants, BrdU incorporation was observed within
the entire neuroepithelium and in some migrating cells
within the mantle layer located underneath the Nkx2.2
domain (Figs. 3C,E). Cyclopamine treatment reduced BrdU
incorporation in the neuroepithelium and blocked prolifera-
tion of the cells migrating under the Nkx2.2 domain in theronal markers. A: Diagram representing ventral neuroepithelial domains and
ted for 2 days under control conditions (B, C, D), or with 4 AM cyclopamine
sion of irx3, marker of neuron progenitors including V2 interneurons (E),
mpared to the corresponding controls (B, C, D).
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neuroepithelial cells showed a 50% reduction after cyclop-
amine treatment (Fig. 3G). This indicates that cell prolifer-
ation in the neuroepithelium is partially controlled by Shh,
substantiating the possibility that its effect on the expansion
of the Nkx2.2 domain was due to proliferation.
To further examine this possibility, we blocked cell
division with aphidicolin, an inhibitor of DNA polymerase
that stops the cell cycle in the early S phase and prevents
neural cell proliferation (Harris and Hartenstein, 1991). E5
spinal cords were cultured for 24 h either under control
conditions or in the presence of 5 AM aphidicolin. In our
system, aphidicolin efficiently blocked cell division, as
shown by total inhibition of BrdU incorporation in the
tissue (Figs. 3H,I). However, the drug affected neither the
size of the Nkx2.2 domain (Figs. 3K,L) nor the positionFig. 5. Shh signalling controls the expression of early astrocyte markers in the neur
(B, D) in the E4 and E6 spinal cord. The AP marker Fgfr3 (B, D) is strongly expr
separated by a region of much lower expression. Note that olig2 (A, C) is express
were cultivated for 2 days under control conditions (E, F, K, L), treated with 4 AM
to in situ hybridization for Fgfr3 (E, G, I), glast (F, H, J), olig2 (K, M) or nkx2.2
ventrally. Note that a small gap of expression (arrowheads) remains at the floor pla
(compare with Fig. 2O). After Shh treatment (100 nM), Fgfr3 (I) and glast (J) ex
expression of olig2 (M) and nkx2.2 (N) dorsally compared to controls (K, L). In ad
neuroepithelium (arrowheads in M, N).of the ventral border of the Pax6 domain (Figs. 3M,N) or
of the olig2 domain (Figs. 3O,P). Finally, this treatment
had no effect on the emergence of O4+ OLPs (Figs.
3Q,R). Thus, the expansion and regression of Nkx2.2
and Pax6 domains and the dorsal shift of the olig2
domain, observed between E5 and E6, result from repat-
terning of ventral neuroepithelial cells rather than from
cell proliferation.
Shh controls emergence of the astroglial lineage in the
spinal cord neuroepithelium
As shown above, late inactivation of Shh signalling leads
to modifications of the expression pattern of ventral tran-
scription factors, raising the question of the consequences of
such inactivation upon the developmental repertoire ofoepithelium. A–D: Comparison of the expression of olig2 (A, C) and Fgfr3
essed in two domains, the floor plate and a median neuroepithelial domain,
ed in the domain of low Fgfr3 (B, D). E–N: Flat-mounted E4 spinal cords
cyclopamine (G–H) or with 100 nM Shh protein (I, J, M, N) and subjected
(L, N). Cyclopamine treatment extends Fgfr3 (G) and glast (H) expression
te border, which presumably corresponds to the Nkx2.2-expressing domain
pression was almost abolished. The same treatment extends the domains of
dition, Shh treatment induces strong expression of both genes in the dorsal
E. Agius et al. / Developmental Biology 270 (2004) 308–321316neural progenitors at this level of the spinal cord. We first
determined whether blocking Shh signalling after E4 altered
the development of ventral neurons. Three transcription
factors, markers of different neuronal subpopulations orig-
inating from progenitor domains located immediately dorsal
and ventral to the olig2 domain, were analysed (Fig. 4A).
These were Irx3, a marker of interneuron progenitors whose
domain of expression abuts dorsally to that of olig2 domain,
MNR2 for motoneurons and sim1 for V3 interneurons
(Briscoe et al., 2000). No obvious modification in the
expression of any of these markers was observed between
control (Figs. 4B–D) and cyclopamine-treated spinal cord
explants (Figs. 4E–G). This suggests that modification of
Shh signalling at this stage no longer has any effect in
ventral neuron formation.
We then tested the possibility that ventral neuroepithe-
lial precursors, prevented from becoming OLs by blocking
Shh signalling, differentiated into astrocytes instead. We
first analysed two markers expressed in astrocyte progen-
itors (APs), the glutamate–aspartate transporter (Glast),Fig. 6. Shh signalling inhibits the development of astrocytes. A–C: Comparis
expression in E11 spinal cord. At this stage, both markers are expressed essentially
8 days to allow differentiation of GFAP+ astrocytes and PLP/DM20+ oligodendrocy
of 100 nM Shh (E, H, K) or with 4 AM cyclopamine (F, L). Under control cond
expressing GFAP mRNA (arrowheads in D) and also displaying the characteristic
DM20 mRNA (arrowheads in J). In the presence of 100 nM Shh, GFAP express
stimulated as seen by increased PLP/DM20 mrRNA expression (K). Conversely,
PLP/DM20 mrRNA expression (L). I: The effects of Shh on GFAP protein
immunoreactivity, using Image Tool software. Shh treatment reduced GFAP stai
cultures ( P < 0.05).and the FGF receptor 3 (Fgfr3). Both markers are
expressed early in radial glia and their expression is
maintained in APs and mature astrocytes in the vertebrate
spinal cord (Hartfuss et al., 2001; Pringle et al., 2003;
Shibata et al., 1997). At E4, Fgfr3 was strongly expressed
in two separate domains, the floor plate and a median
neuroepithelial domain, located dorsal to the olig2 expres-
sion domain, with a much lower level of expression
between these two regions (Figs. 5A,B). Glast expression
followed a very similar pattern (not shown). These expres-
sion patterns were not modified after E6 (Figs. 5C,D), at
least up to E9 (Pringle et al., 2003).
Similar patterns of expression were found in spinal cord
explants cultivated under control conditions (Figs. 5E,F).
Strikingly, however, cyclopamine treatment resulted in ven-
tral extension of the neuroepithelial domain of expression of
both genes (Figs. 5G,H). However, a gap of expression still
remained just above the floor plate, at the level of the
Nkx2.2 domain (see Fig. 2O), suggesting that these markers
were not expressed by Nkx2.2+ cells. These results suggeston of GFAP mRNA (A), GFAP protein (B) and PLP/DM20 mRNA (C)
in the ventral white matter. D–L: E4 Spinal cord explants cultivated for 7 or
tes. Explants were grown under control conditions (D, G, J), in the presence
itions, the latero-ventral part of the explants contains numerous astrocytes
filamentous GFAP staining (arrowheads in G), and OLs expressing PLP/
ion is drastically reduced (E, H), while OL development is concomitantly
cyclopamine treatment stimulates GFAP expression (F) while it abolishes
expression were quantified by measuring the surface covered by GFAP
ning by 50%. Asterisk: Significant difference between control and treated
E. Agius et al. / Developmental Biology 270 (2004) 308–321 317that endogenous Shh signalling prevents the expression of
glast and Fgfr3. To further address this possibility, E4 spinal
cord explants were treated with Shh protein (100 nM) for 48
h. This treatment caused a drastic reduction in the expres-
sion of both markers within the neuroepithelium (Figs. 5I,J).
A similar reduction was also seen after electroporation of
the E4 spinal cord with a shh-expressing plasmid (data not
shown). Interestingly, expression of both genes in the floor
plate was not affected by modifications of Shh signalling,
suggesting an alternative control mechanism in the latter cell
type.
Since Olig2 has recently been shown to repress astrocyte
formation (Fukuda et al., 2004; Gabay et al., 2003), we also
analysed the consequences of Shh treatment on olig2
expression in this system. As expected, 100 nM Shh caused
marked extension of olig2 domain in the ventral neuro-
epithelium (Fig. 5M) compared to untreated spinal cords
(Fig. 5K). The extension of the olig2 domain is concomitant
to the dorsal extension of the nkx2.2 domain (Figs. 5N,L)
confirming that Shh is able to induce coexpression of both
genes in ventral neuroepithelial cells. In addition, it induced
coexpression of both factors in the dorsal neuroepithelium
(arrowheads in Figs. 5M,N), in keeping with the observa-
tions that Shh can promote oligodendrocyte differentiation
in dorsal spinal cord tissue (Poncet et al., 1996). However,
these transcription factors were not induced along the entire
neuroepithelium: a region where glast and Fgfr3 are nor-
mally expressed remained deprived of olig2 and nkx2.2
expression (Figs. 5M,N).
Taken together, the results of our experiments suggest
that Shh signalling specifically restricts the ventral expres-
sion of astrocyte lineage markers while promoting OL
development in the ventral neuroepithelium.
To assess long-term effects of Shh signalling on astrocyte
specification, GFAP expression, a property of mature astro-
cytes, was analysed under the same experimental condi-
tions. OL differentiation was monitored in parallel by
studying the expression of the myelin marker PLP/DM20.
In the E11 spinal cord, both GFAP and PLP/DM20 are
expressed in cells migrating in the ventral white matter
(Figs. 6A,B). Under control conditions, after 7 or 8 days of
culture, GFAP+ astrocytes developed and accumulated in
the latero-ventral aspect of the explants (arrowheads in Figs.
6D,G). Small numbers of PLP/DM20+ OLs could also be
detected at this stage in the same location (arrowheads in
Fig. 6J). Shh treatment drastically reduced GFAP expression
in the explants, both at RNA and protein levels (Figs. 6E,H).
Quantification of GFAP immunostaining indicated a 50%
reduction in the area covered by immunoreactive protein
(Fig. 6I), suggesting impaired astrocyte development. Con-
versely, cyclopamine treatment clearly enhanced the number
of cells expressing GFAP (Fig. 6F), which accumulated in
the median region of the explant. As expected, Shh treat-
ment strongly stimulated OL differentiation, as judged from
increased PLP/DM20 expression (Fig. 6K), whereas cyclop-
amine totally abolished it (Fig. 6L).Taken together, these results suggest that, during the
development of the chick spinal cord, Shh signalling
represses specification of the astrocyte lineage in the ven-
tral-most region of the neuroepithelium, while concomitant-
ly stimulating the emergence of OLPs in this domain.Discussion
Studies on the mechanisms of specification of OLs in the
chick ventral spinal cord has resulted in the identification of
numerous extracellular (i.e., Shh, BMPs) and intracellular
(i.e., transcription factors) proteins involved in this process.
In this work, we show that Shh signalling controls OL
specification by tightly regulating the expression of ventral
transcription factors involved in oligodendrogenesis, and it
does so by repatterning the ventral neuroepithelium. This
results in the appearance of a population of ventral neuro-
epithelial cells coexpressing olig2 and nkx2.2, engaged
along the OL lineage. Conversely, at the same time, Shh
signalling appears to inhibit the appearance of the astrocyte
lineage in the ventral-most aspect of the neuroepithelium
leading to the restriction of APs dorsally to OLPs.
Shh signalling repatterns the neuroepithelium between E5
and E6
During early development, various classes of neurons are
generated at defined positions in the ventral neural tube
through the combined expression of a variety of transcrip-
tion factors (Briscoe and Ericson, 1999). Among these,
some are probably involved in gliogenesis, as shown by
the fact that both neuronal and glial differentiation can be
affected by their loss of function. For example, loss of
function of nkx2.2 modifies the production of ventral
neuronal types (Briscoe et al., 1999) and induces an increase
in the production of Olig1/Olig2-positive cells but eventu-
ally causes a reduction in the number of mature OLs (Qi et
al., 2001). In Small eye (Pax6-deficient) mice, the origin of
MNs and OLPs are shifted dorsally and their differentiation
is delayed (Sun et al., 1998). Finally, loss of function of olig
genes severely affects motoneuron development and totally
abolishes that of OLs (Lu et al., 2002; Park et al., 2002;
Takebayashi et al., 2002; Zhou and Anderson, 2002).
Expression of these transcription factors is regulated
from the early stages through graded Shh secreted by the
floor plate (reviewed in Briscoe and Ericson, 1999). The
present results demonstrate that at later stages, during the
gliogenic phase, ongoing Shh signalling is also required to
(i) maintain olig2 expression and (ii) regulate changes in the
expression domains of pax6 and nkx2.2. In particular, dorsal
extension of the Nkx2.2 domain and simultaneous regres-
sion of the Pax6 domain appear essential for OLP specifi-
cation. Shh not only controls domain repatterning but also
neural precursor proliferation in certain CNS areas (Good-
rich et al., 1997; Rowitch et al., 1999). Our experiments
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ate the two mechanisms and showed that dorsal extension of
the Nkx2.2 domain does not rely on proliferation, and thus
is primarily due to repatterning. This repatterning, which
occurs in the total absence of cell proliferation, leads to
normal OLP development, judging by the normal number
and position of OLPs developing in the presence of aphi-
dicolin. Thus, cell proliferation at the time of Nkx2.2
domain extension does not appear to be a prerequisite for
OLP specification. Our results also indicate that neuro-
epithelial cells expressing low Pax6 before E5 will subse-
quently express Nkx2.2. Whether Shh primarily controls the
regression of Pax6 or the dorsal extension of Nkx2.2
remains to be investigated, since this morphogen has been
shown to control, negatively and positively, the expression
of both transcription factors (Barth and Wilson, 1995).
The Shh-dependent rapid change of transcription factor
expression between E5 and E6 can only be explained by an
abrupt change in Shh signalling. Further work is required to
discriminate between increased Shh release and increased
sensitivity of the Shh-target ventral neuroepithelial cells.
This also leads to the possibility that Shh would not trigger
itself glial fate choice, but would direct OLP specification
out of a glial progenitor. In this view, other extrinsic or
intrinsic mechanisms, for example the transcription factor
Sox9 (Stolt et al., 2003), would be required to enable a
switch between neurogenesis and oligodendrogenesis.
In any case, our experiments demonstrate that active Shh
signalling is absolutely required for the maintenance of
Olig2 expression. Thus, Shh signalling appears necessary
and sufficient to induce the coexpression of olig2 and
nkx2.2 genes in the ventral neuroepithelium concomitantly
with oligodendrogenesis. Initially, olig2 and nkx2.2 are
expressed in mutually exclusive domains and nkx2.2 has
been shown to repress olig2 expression (Novitch et al.,
2001). Why olig2 is no longer repressed by nkx2.2 during
the gliogenic phase remains to be determined.
Coexpression of both olig2 and nkx2.2 genes is required
to induce ectopic oligodendrogenesis in the chick spinal
cord (Zhou et al., 2001). Additionally, Shh has been shown
to induce OLs in dorsal spinal cord explants (Orentas et al.,
1999; Soula et al., 2001). In our experiments, a large ectopic
nkx2.2, olig2 coexpression domain was observed in dorsal
neuroepithelium after Shh treatment, reinforcing the con-
clusion that the OL-inducing activity of Shh is mediated by
its ability to allow olig2-nkx2.2 coexpression in neural
progenitors. Interestingly, neither nkx2.2 and olig2, nor
OLs (P. Kan and P. Cochard, unpublished) can be induced
in the intermediate region of the neuroepithelium. This
corresponds to the high pax6-expressing domain that was
already shown not to be affected by increased Shh signalling
at early stages of development (Patten and Placzek, 2002).
In fact, reduction in Pax6 expression requires both increased
Shh and coexpression of shh with chordin, a BMP inhibitor
(Patten and Placzek, 2002). This indicates that the transcrip-
tion factor repertoire expressed by ventral neuroepithelialcells is controlled not only by Shh but also by other factors
such as BMPs. It is noteworthy that a similar dual control
has already been proposed to regulate OL emergence
(Mekki-Dauriac et al., 2002). Thus, the finely regulated
repatterning observed in the ventral neuroepithelium be-
tween E5 and E6 may involve several extracellular signal-
ling molecules.
O4 immunostaining studies indicate that OLs arise from
the entire nkx2.2-expressing domain (Soula et al., 2001),
part of which only also expresses olig2. This suggests that at
least two populations of OLP are produced in the ventral
neuroepithelium. Studies in the mouse and the chick have
provided additional data supporting this conclusion (Fu et
al., 2002; Lee et al., 2003; Perez Villegas et al., 1999). In the
chick, both OLP populations are induced by Shh, since
OLPs identified by O4 expression are totally absent when
Shh signalling is blocked (Orentas et al., 1999; Soula et al.,
2001). The molecular mechanisms responsible for the emer-
gence of the Olig2 population are still unknown. It is
possible that a difference in the concentration or the avail-
ability of Shh is involved since dose-dependent effects of
Shh are clearly important during neurogenesis (Briscoe and
Ericson, 1999). Alternatively, different relay mechanisms
downstream of Shh could also be involved. For example,
Olig3 expression (Takebayashi et al., 2002) could be ini-
tially involved in the specification of a Nkx2.2+/Olig2
OLP subpopulation.
Extracellular signals that regulate both astrocyte and OL
lineages
Analysis of the expression of Fgfr3 and glast (Pringle et
al., 1998, 2003 and the present results) strongly suggests
that APs and OLPs are spatially segregated in the neuro-
epithelium. Here we show by gain- and loss-of-function
experiments that Shh not only induces OLP specification
but also negatively controls the expression of early AP
markers and the numbers of differentiated astrocytes, sug-
gesting that Shh inhibits AP specification. On the other
hand, studies in mice have allowed to characterize a glial-
restricted progenitor with the ability to give rise to astro-
cytes and OLs (Rao and Mayer-Proschel, 1997). Our results
suggest the interesting possibility that neuroepithelial pre-
cursors, at the stages studied here, indeed have the potential
to generate both lineages, but do not actually do so because
they are directed towards one or the other of these fates
depending on local Shh signalling. In addition to Shh, other
environmental clues may also control this choice. For
example, BMPs, which in vitro can promote astroglial
differentiation and concomitantly restrict the oligodendrog-
lial fate (Mabie et al., 1997; Mehler et al., 2000), have been
shown to inhibit OLP specification in vivo (Mekki-Dauriac
et al., 2002) and thus may also participate in astrocyte
specification in vivo.
Expression of Fgfr3 and glast is excluded from the
ventral neuroepithelium by Shh signalling. This raises the
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dorsal neuroepithelium. A possible explanation is that cells
in the dorsal neuroepithelium are more immature (Megason
and McMahon, 2002). Alternatively, extracellular factors
expressed dorsally could repress the expression of glast and
Fgfr3 in the dorsal neuroepithelium. Wnt genes, which are
expressed dorsally and have been shown to promote prolif-
eration and reduce differentiation (Megason and McMahon,
2002), are possible candidates for the mediation of this
dorsal inhibition, although their role in astrocyte specifica-
tion has not yet been documented.
Molecular mechanisms that control astrocyte marker
expression
In the chick spinal cord, olig2 and Fgfr3/glast are
expressed in nonoverlapping neuroepithelial domains
(Pringle et al., 2003 and the present results). In the
olig1/2 double mutant mice, in which OL differentiation
is abolished, the cells normally fated to become OLs (i.e.,
expressing GFP under the control of the olig2 promoter)
differentiate along the astrocyte lineage as shown by
GFAP expression (Zhou and Anderson, 2002). In addi-
tion, enforced expression of Olig1 or Olig2 in mouse
telencephalic neural cells and neurospheres in vitro inhib-
its astrocytic differentiation (Fukuda et al., 2004; Gabay et
al., 2003), indicating that Olig2 plays a direct role in
preventing astrocyte development. In the present work,
cyclopamine treatment, which abolished olig2 expression,
resulted in a ventral extension of astroglial marker ex-
pression. This shows that Shh signalling inhibits the
ventral extension of APs by maintaining olig2 expression.
However, two different observations suggest that other
molecular factors may be involved. First, after cyclop-
amine treatment, expression of Fgfr3 and glast was still
excluded from the ventral-most part of the neuroepithe-
lium that expresses nkx2.2, but not olig2, suggesting that
the former may also prevent AP development. In support
of this possibility, BMP4 overexpression, which also
abolishes olig2 expression, does not affect Nkx2.2 expres-
sion and does not appear to modify the ventral border of
the Glast expression domain (Mekki-Dauriac et al., 2002).
Second, Shh treatment of the spinal cord totally abolished
expression of Fgfr3 and glast from the intermediate
region of the neuroepithelium without concomitant induc-
tion of olig2 and nkx2.2.
Transcription factors involved in astrocyte specification
have not yet been characterized. However, the presence of
E-boxes in the GFAP promoter (Lee et al., 2003) suggests
that at least some bHLH factors are involved in either the
specification or the differentiation of astrocytes. In the light
of what is now known of the role of the olig2 gene in the
emergence of motoneurons and the OL lineage (Zhou and
Anderson, 2002), such bHLH encoding genes may be
involved in the successive specification of interneurons
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